Boehringer Ingelheim Human Pharma Clinical Pipeline
Learn more about our R&D approach
Selection of projects in January 2023
Phase 1
GLP-1/FGF21 agonist
CardioMetabolic Diseases
Partnered project or acquired asset
Heart disease modulator
CardioMetabolic Diseases
Key pipeline advance*
Partnered project or acquired asset
B7-H6/CD3 T-cell engager
Oncology
Partnered project or acquired assetCD137/FAP agonist
Oncology
Partnered project or acquired asset
DLL3/CD3 T-cell engager
Oncology
Partnered project or acquired asset
Ezabenlimab
PD-1 antibody
Oncology
Being investigated only in combination with other therapies
HER2 TKI
Oncology
Heterologous prime boost vaccine
Oncology
Key pipeline advance*
Partnered project or acquired asset
KISIMA® cancer vaccine
Oncology
Partnered project or acquired asset
KRAS (G12C) inhibitor
Oncology
Partnered project or acquired asset
pan KRAS SOS1 inhibitor
Oncology
Being investigated only in combination with other therapies
Partnered project or acquired asset
MDM2-p53 antagonist
Oncology
Partnered project or acquired asset
SIRPalpha antagonist
Oncology
Partnered project or acquired asset
TRAILR2/CDH17 antibody
Oncology
VSV-GP
Oncology
Key pipeline advance*
Partnered project or acquired asset
Ion channel inhibitor
Respiratory Diseases
Key pipeline advance*
Lysophospholipase inhibitor
Immunology
Key pipeline advance*
PD-1 antibody
Immunology
Digital therapeutic
CNS Diseases
Key pipeline advance*
Partnered project or acquired asset
NMDA regulator
CNS Diseases
Phosphodiesterase inhibitor
CNS Diseases
Partnered project or acquired asset
Phospholipid modulator
Retinal Diseases
Key pipeline advance*
Vascular modulator
Retinal Diseases
Key pipeline advance*
Phase 2
BI 456906
GLP1/GCGR agonist | Obesity
CardioMetabolic Diseases
Partnered project or acquired asset
BI 456906
GLP1/GCGR agonist | NASH
CardioMetabolic Diseases
Key pipeline advance*
Partnered project or acquired asset
BI 685509
sGC activator | CSPH
CardioMetabolic Diseases
Key pipeline advance*
BI 764198
TRPC6 inhibitor | FSGS
CardioMetabolic Diseases
Key pipeline advance*
Partnered project or acquired asset
Empagliflozin + BI 690517
SGLT2 inhibitor + aldosterone synthase inhibitor | CKD
CardioMetabolic Diseases
Key pipeline advance*
BI 907828
MDM2-p53 antagonist | DDLPS
Oncology
Key pipeline advance*
Partnered project or acquired asset
BI 907828
MDM2-p53 antagonist | 2L+ BTC
Oncology
Key pipeline advance*
Partnered project or acquired asset
BI 1291583
CatC inhibitor | nCFB
Respiratory Diseases
Key pipeline advance*
Partnered project or acquired asset
BI 706321
Kinase inhibitor | CD
Immunology
Key pipeline advance*
BI 685509
sGC activator | SSc
Immunology
Key pipeline advance*
Spesolimab (BI 655130)
IL36R antibody | HS
Immunology
Spesolimab (BI 655130)
IL36R antibody | GPP flare prevention
Immunology
Key pipeline advance*
BI 1358894
BPD
CNS Diseases
BI 1358894
MDD
CNS Diseases
Partnered project or acquired asset
BI 1358894
PTSD
CNS Diseases
Key pipeline advance*
Partnered project or acquired asset
BI 765128
Ischemia modulator | DMI
Retinal Diseases
Key pipeline advance*
BI 764524
Sema3A antibody | DMI
Retinal Diseases
Phase 3
Empagliflozin / New indication
SGLT2 inhibitor | Prevention of HF post MI
CardioMetabolic Diseases
BI 1015550
PDE4B inhibitor | IPF
Respiratory Diseases
Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration
Key pipeline advance*
BI 1015550
PDE4B inhibitor | PPF
Respiratory Diseases
Key pipeline advance*
Iclepertin
GlyT1 inhibitor | CIAS
CNS Diseases
Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration
Registration
Empagliflozin / New indication
SGLT2 inhibitor | CKD
CardioMetabolic Diseases
Key pipeline advance*
*Key pipeline advance: January 2022 – January 2023
Indication abbreviations
2L+ BTC: 2nd line treatment, advanced biliary tract cancer
BPD: Borderline personality disorder
CD: Crohn’s disease
CIAS: Cognitive impairment associated with schizophrenia
CKD: Chronic kidney disease
COPD: Chronic obstructive pulmonary disease
CSPH: Clinically significant portal hypertension
DDLPS: Dedifferentiated liposarcoma
DMI: Diabetic macular ischemia
FSGS: Focal segmental glomerulosclerosis
GPP: Generalized pustular psoriasis
HF: Heart failure
HS: Hidradenitis suppurativa
IPF: Idiopathic pulmonary fibrosis
MDD: Major depressive disorder
MI: Myocardial infarction
NASH: Non-alcoholic steatohepatitis
nCFB: non-cystic fibrosis bronchiectasis
PPF: Progressive pulmonary fibrosis
PTSD: Post-traumatic stress disorder
SSc: Systemic sclerosis